Company News- October 1, 2007 Redpoint Bio Names Scott Siegel, Ph.D. as Vice President of Corporate Development Redpoint Bio Corporation (OTCBB: RPBC), a company developing compounds to improve the taste of pharmaceutical, food and beverage products, announced earlier today the appointment of Scott A. Siegel, Ph.D., to the position of Vice President of Corporate Development.In his new role, Dr. Siegel will be responsible for the Company's business development strategy and execution and will report directly to Dr. Ray Salemme, Chief Executive Officer.
Commenting on today's news, Dr. Salemme noted, "We are delighted to welcome Scott
in this key position.
With over 20 years of commercial, business development, and research and development expertise with a broad array of life sciences companies, Scott
brings to Redpoint
a truly well-rounded set of capabilities.We intend to leverage all of these as we move forward aggressively with product development and additional partnership opportunities for our taste enhancer and bitter blocker programs."Prior to joining Redpoint Bio, Dr. Siegel, 50, spent eight years with Johnson & Johnson, most recently as Worldwide Strategic Marketing New Business Development Director, with responsibility for commercial review of global oncology therapeutics licensing opportunities.
In this capacity, he
lead the establishment of a worldwide business case for deals by creating and leading cross-functional assessment teams consisting of Johnson & Johnson
affiliates located across the globe. Before that, Dr. Siegel served in various positions, including Executive Director, New Business Development and Senior Director, at Ortho Biotech Products, L.P., also a Johnson & Johnson affiliate.
While there, Dr. Siegel
was responsible for new business development strategy and technology assessment with a focus in the areas of drug delivery and lifecycle management, among others.While at Ortho Biotech he
lead or played a key role in the transaction and execution of several licensing agreements with US and international business partners. Earlier in his career, Dr. Siegel served as Senior Director, Preclinical Research and Product Development for Phytera, Inc.; Associate Director, Immunobiology Research and Development for Centocor, Inc., and; Section Leader, Immunodiagnostics Department at Becton Dickinson and Company.He also served, from 1988 to 1995, as Adjunct Associate Professor of Microbiology at the University of Pennsylvania, School of Dental Medicine. Dr. Siegel earned his Bachelor of Science degree from the State University of New York, College at New Paltz, where he majored in biology.Dr. Siegel also earned a Ph.D. in biochemistry from the State University of New York, Downstate Medical Center and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine. Dr. Siegel is a co-inventor of Remicade , a drug used to treat autoimmune disorders.He is the author of more than 30 scientific and business abstracts and publications, holds 12 issued patents and is a frequent speaker and panel moderator on issues relating to drug delivery, business development and business strategy for the Pharmaceutical and Biotechnology industries.